

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-30. (Canceled)

31. (Previously Presented) A method of screening an agent for toxic activity and a pharmacological activity *in vivo* comprising:

administering the agent to a plurality of teleosts *in vivo*;

detecting *in vitro* or *in situ* a change in expression of a protein or mRNA in a specific organ or tissue of the teleost responsive to the agent relative to the expression of the protein or mRNA in the specific organ or tissue of a teleost to which the agent has not been administered, the change in expression indicating toxic activity in at least one tissue or organ of the teleost administered the agent; and

detecting *in vitro* or *in situ* a change in a different teleost administered the agent relative to a control teleost not administered the agent, wherein the change is indicative of the pharmacological activity.

32. (Canceled)

33. (Currently Amended) The method of claim 31, wherein the change in expression of the protein or mRNA in the teleost indicating toxic activity is detected in at least two tissues, at least two organs, or at least one tissue and one organ simultaneously.

34. (Canceled)

35. (Previously Presented) The method of claim 31, wherein a response is detected indicating toxic activity in at least two teleosts simultaneously.

36. (Previously Presented) The method of claim 35, wherein each of said at least two teleosts is contained in a separate well of a multi-well plate.

37. (Previously Presented) The method of claim 36, wherein the wells of the multi-well plate have a volume of 300 microliters or smaller per well.

38. (Previously Presented) The method of claim 36, wherein the wells contain the teleosts in a volume of 50-200 microliters per well.

39 (Previously Presented) The method of claim 31, wherein the plurality of teleosts are contained within separate wells of a multi-well plate having a volume of 300 microliters or smaller.

40. (Previously Presented) The method of claim 31, wherein the plurality of teleosts are contained within separate wells of a multi-well plate in a volume of 50-200 microliters.

41-42. (Canceled)

43. (Currently Amended) The method of claim 31[[42]], wherein the change in expression of the protein or mRNA in the teleost indicating toxic activity is detected over time.

44. (Canceled)

45. (Currently Amended) The method of claim 43[[44]], wherein the change in expression of the protein or mRNA in the teleost indicating toxic activity is detected over time at predetermined intervals.

46-49. (Canceled)

50. (Currently Amended) The method of claim 31[[42]], wherein at least one[[the]] teleost administered the agent and at least one~~the~~ control teleost to which the agent has not been administered are contained in separate wells of a single multi-well plate.

51. (Previously Presented) The method of claim 50, wherein the wells of the multi-well plate have a volume of 300 microliters or smaller per well.

52. (Previously Presented) The method of claim 50, wherein the wells of the multi-well plate have a volume of greater than 300 microliters per well.

53. (Canceled)

54. (Previously Presented) The method of claim 31, wherein the plurality of teleosts are zebrafish.

55. (Canceled)

56. (Previously Presented) The method of claim 31, wherein the plurality of teleosts are wild-type teleosts.

57. (Canceled)

58. (New) The method of claim 54, wherein the different teleost is a zebrafish.

59. (New) The method of claim 31, wherein the plurality of teleosts and the different teleost are teleost embryos.

60. (New) The method of claim 31, wherein the plurality of teleosts are larval or adult teleosts.